共 177 条
[11]
Lyman GH(2009)Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia Cancer 115 4839-4848
[12]
Smith TJ(2015)Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: Does timing of administration matter? Supportive Care in Cancer. 22 2167-2175
[13]
Khatcheressian J(2015)Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice Supportive Care in Cancer. 31 4290-4296
[14]
Lyman GH(2014)Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma Support Care Cancer 27 79-86
[15]
Ozer H(2013)Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia J Clin Oncol 103 979-982
[16]
Armitage JO(2011)Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study Curr Med Res Opin 31 1069-1081
[17]
Balducci L(2011)Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes J Natl Cancer Inst 7 225-228
[18]
Caggiano V(2009)Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study Clin Ther 13 337-348
[19]
Weiss RV(2009)Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer J Support Oncol 29 361-363
[20]
Rickert TS(2007)Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices J Manag Care Pharm 40 402-407